Literature DB >> 17245556

Selection for mutations in the cDNAs of transgenic mice upon expression of an embryonic lethal protein.

Katja Schuster1, Linda C Harris.   

Abstract

The generation of transgenic mouse models to study in vivo functions of specific proteins has become common practice. In addition, PCR technology allows efficient and rapid identification of founder mice by the analysis of tail tip DNA. Whilst the DNA construct used in the microinjection of one-cell-stage embryos is usually sequenced it is not common practice to sequence the PCR product once the transgene has been inserted into the mouse genome. In this report we describe why sequencing of inserted transgenes is important. Upon generation of transgenic mice expressing a splice variant of MDM2, MDM2-A, three of four founders contained mutations within the Mdm2-a cDNA sequence. The observation that selection against expression of wild-type MDM2-A resulted in the generation of mice expressing mutant transgenes highlights the importance of sequencing the transgenes of founder mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245556     DOI: 10.1007/s11248-006-9065-8

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  9 in total

1.  The RING domain of Mdm2 can inhibit cell proliferation.

Authors:  Jinjun Dang; Mei-Ling Kuo; Christine M Eischen; Lilia Stepanova; Charles J Sherr; Martine F Roussel
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

Review 2.  MDM2 function.

Authors:  G Lozano; R Montes de Oca Luna
Journal:  Biochim Biophys Acta       Date:  1998-04-17

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Gene splicing by overlap extension.

Authors:  R M Horton; S N Ho; J K Pullen; H D Hunt; Z Cai; L R Pease
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

5.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.

Authors:  S C Evans; M Viswanathan; J D Grier; M Narayana; A K El-Naggar; G Lozano
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

6.  Craniofacial abnormalities induced by ectopic expression of the homeobox gene Hox-1.1 in transgenic mice.

Authors:  R Balling; G Mutter; P Gruss; M Kessel
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

7.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Authors:  P M Siegel; D L Dankort; W R Hardy; W J Muller
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

8.  Chromosomal mapping and zygosity check of transgenes based on flanking genome sequences determined by genomic walking.

Authors:  Akira Noguchi; Naho Takekawa; Thorbjorg Einarsdottir; Minako Koura; Yoko Noguchi; Kaoru Takano; Yoshie Yamamoto; Junichiro Matsuda; Osamu Suzuki
Journal:  Exp Anim       Date:  2004-04

Review 9.  Alternative and aberrant splicing of MDM2 mRNA in human cancer.

Authors:  Frank Bartel; Helge Taubert; Linda C Harris
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

  9 in total
  2 in total

1.  MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence.

Authors:  Erin L Volk; Katja Schuster; Katie M Nemeth; Liying Fan; Linda C Harris
Journal:  Dis Model Mech       Date:  2008-12-22       Impact factor: 5.758

2.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.